Salts 756
AssigneesAstraZeneca AB, Dainippon Sumitomo Pharma Co., Ltd.
InventorsNicholas James Bennett, Thomas McInally, Austen Pimm, Yoshiaki Isobe
Life of this patent
Estimating the term…
Abstract
The invention provides salts of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate, pharmaceutical compositions containing them and their use in therapy.
Claims35
Form A of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate disaccharin salt, characterised in that said Form A has an X-ray powder diffraction pattern with specific peaks at 2θ about 9.2°, 13.9°, 14.9° or 15.2° when measured using CuKα radiation.
Form B of 4-(dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate disaccharin salt, characterised in that said Form B has an X-ray powder diffraction pattern with specific peaks at 2θ about=12.0°, 12.5°, 16.4° or 19.8° when measured using CuKα radiation.
4-(Dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate difumaric acid salt, characterised in that said salt has an X-ray powder diffraction pattern with specific peaks at 2θ about =9.1°, 14.2°, 15.8° or 20.4° when measured using CuKα radiation.
4-(Dimethylamino)butyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate di-1-hydroxy-2-naphthoic acid salt, characterised in that said salt has an X-ray powder diffraction pattern with specific peaks at 2θ about =8.3°, 16.6°, 19.4° or 23.4° when measured using CuKα radiation.
4-(Dimethylamino)butyl 2-4-((2-amino-4-meth-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate mono-benzoic acid salt, characterised in that said salt has an X-ray powder diffraction pattern with specific peaks at 2θ about =6.3°, 9.3°, 17.8° or 23.8° when measured using CuKα radiation.
Dependencies are inferred from the claim text.